跳到正文
研踪PaperTrail
← 研踪 PaperTrail

arXiv:2611.22230 · v1

Discovery of new antiviral agents through artificial intelligence: in vitro and in vivo results

首次提交 2026-11-17 13:22
版本更新 2026-11-17 13:22
雷达观测 2026-11-18 19:43
arXiv ↗PDF ↗

摘要

In this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses. A total of 60291 compounds were generated, of which 86.5% displayed superior physicochemical properties compared to oseltamivir. After narrowing down the selection through computational filters, nine compounds with non-sialic acid-like structures were selected for in vitro experiments. We identified two compounds, DS-22-inf-009 and DS-22-inf-021 that effectively inhibited the NAs of both influenza A and B viruses (IAV and IBV), including H275Y mutant strains at low micromolar concentrations. Molecular dynamics simulations revealed a similar pattern of interaction with amino acid residues as oseltamivir. In cell-based assays, DS-22-inf-009 and DS-22-inf-021 inhibited IAV and IBV in a dose-dependent manner with EC50 values ranging from 0.29 uM to 2.31 uM. Furthermore, animal experiments showed that both DS-22-inf-009 and DS-22-inf-021 exerted antiviral activity in mice, conferring 65% and 85% protection from IAV (H1N1 pdm09), and 65% and 100% protection from IBV (Yamagata lineage), respectively. Thus, these findings demonstrate the potential of RL to generate compounds with promising antiviral properties.

作者备注:Accepted manuscript. 13 pages, 5 figures; supplementary material included (supplementary text, Tables S1-S2, Figures S1-S5). Published in Antiviral Research 222 (2024) 105818

期刊信息:Antiviral Research 222 (2024) 105818

AI 论文解读

基于摘要 · 非全文审阅

此版本尚未生成 AI 解读。解读由后台任务生成并按论文版本保存,登录后共享已有结果。

版本差异

目前只收录了一个版本。收录下一版后,可以对照标题、作者、分类和摘要。

观测到的版本

相邻记录可能跳过中间版本;首次发现 v2 及以上也会标为版本更新。

v1 · 2026-11-17 13:22 · 最新观测版本

Discovery of new antiviral agents through artificial intelligence: in vitro and in vivo results

In this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses. A total of 60291 compounds were generated, of which 86.5% displayed superior physicochemical properties compared to oseltamivir. After narrowing down the selection through computational filters, nine compounds with non-sialic acid-like structures were selected for in vitro experiments. We identified two compounds, DS-22-inf-009 and DS-22-inf-021 that effectively inhibited the NAs of both influenza A and B viruses (IAV and IBV), including H275Y mutant strains at low micromolar concentrations. Molecular dynamics simulations revealed a similar pattern of interaction with amino acid residues as oseltamivir. In cell-based assays, DS-22-inf-009 and DS-22-inf-021 inhibited IAV and IBV in a dose-dependent manner with EC50 values ranging from 0.29 uM to 2.31 uM. Furthermore, animal experiments showed that both DS-22-inf-009 and DS-22-inf-021 exerted antiviral activity in mice, conferring 65% and 85% protection from IAV (H1N1 pdm09), and 65% and 100% protection from IBV (Yamagata lineage), respectively. Thus, these findings demonstrate the potential of RL to generate compounds with promising antiviral properties.

查看此版本解读 →查看此版本原文 ↗